Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
Stablecoins can play a strategic role in liquidity and risk management. This short intro explains when to hold stablecoins in a portfolio for balance and flexibility.
18,427 articlesTwo top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
A consortium led by Barry Diller has proposed a $12.4 billion bid to take MGM Resorts private, a move that could resh...
A leading portfolio strategist warns that the market could enter another lost decade of real returns as valuations st...
Variant has closed a $222 million fund aimed at early-stage crypto and AI ventures that expand user autonomy in finan...
Meta Platforms stock crushed the market today as Meta rolled out a business-focused AI tool worldwide. Investors weig...
A stock trading at a discount may be tempting, but value comes with risk. Learn why this stock won’t stay cheap for l...
Rivian stock moved higher this week without a formal press release, boosted by direct investor outreach and renewed i...
SpaceX stunned markets by setting a fixed IPO price of $135. Is this a bold power move or a warning sign for investor...
As crypto markets swing, choosing the right project matters. This guide compares XRP and Cardano on technology, regul...
An 11% one-day slide in the SPDR S&P Semiconductor ETF underscores how equal-weight funds magnify single-name moves, ...
Alphabet is riding a rapid AI infrastructure expansion that could push Google stock toward $500. Cloud revenue is sur...
A high-profile nod from a tech legend can spark instant moves in AI chip stocks. This guide explains how to separate ...